A new era in pharmaceutical manufacturing has dawned. Varda Space Industries, a pioneering company, has successfully manufactured a sample of HIV medication onboard its spacecraft, marking a significant step towards space-based drug production.
This achievement paves the way for the creation of drugs in orbit that hold immense potential for improving healthcare here on Earth.
A Mission Accomplished: Creating Drugs in Zero Gravity
The journey began in June 2023 when a Varda spacecraft, W-1, embarked on its mission aboard a SpaceX Falcon 9 rocket. Tucked within this spacecraft was a miniaturized, automated laboratory. Over the course of its eight-month mission, this lab successfully produced a specific form of ritonavir, a crucial component in HIV treatment. While seemingly ordinary, this feat represents a major breakthrough. The version of ritonavir manufactured is known for its instability, making its successful creation and return to Earth a testament to Varda’s innovative technology.
Why Manufacture Drugs in Space?
One might question the rationale behind this celestial venture. After all, drug production is already a complex and expensive endeavor on Earth. The answer lies in a fascinating phenomenon – crystallization. In many drugs, the crystallization process significantly impacts factors like manufacturing costs, overall quality, drug stability, and ultimately, its effectiveness in patients. Additionally, the crystallization method determines whether a drug can be delivered as a convenient pill or requires an intravenous (IV) injection.
Interestingly, microgravity, the near absence of gravity experienced in space, presents a unique advantage. Under these conditions, scientists can achieve finer control over the crystallization process, allowing for the cultivation of specific crystal formations that are difficult, or even impossible, to achieve on Earth. This is precisely why protein crystallization experiments have been ongoing aboard the International Space Station (ISS) for over two decades. Pharmaceutical giants like Bristol Myers Squibb and Lilly have also recognized this potential, conducting their own protein crystallization experiments on the ISS in recent years.
A breakthrough experiment conducted in 2019 on the ISS with Merck’s cancer drug, Keytruda, serves as a prime example. This research demonstrated that microgravity enabled the creation of stable crystal forms of Keytruda. These crystals could be administered through injection and stored at room temperature – a significant improvement over the Earth-made version, which requires refrigeration and IV administration. The space-manufactured crystals not only offered greater convenience for patients but also potentially opened doors for new treatment options and improved drug efficacy.
Varda’s co-founder, Delian Asparouhov, acknowledges the potential of space-based manufacturing but also highlights the limitations of the ISS. “The cadence has been way too low and the costs have been way too high,” he states. The ISS, designed to carry astronauts, incurs immense operational costs, and astronaut presence isn’t necessarily required for the core function of drug production. Astronaut time is better spent conducting research experiments or performing maintenance tasks that require human intervention.
Varda’s Vision: A Dedicated Platform for Space-based Manufacturing
This realization led to the founding of Varda in 2020. The company envisions a future where reusable, automated manufacturing satellites operate in orbit. These satellites would house miniaturized laboratories equipped with cutting-edge technology for precise crystal formation and drug synthesis. Unlike the ISS, these dedicated production facilities would be optimized for cost-effective, large-scale drug manufacturing. Varda’s successful demonstration mission with W-1 marks a significant milestone in this pursuit.
The company looks beyond small batches. Asparouhov suggests that Varda’s future crafts could be optimized to manufacture ingredients for a substantial quantity, like 200,000 doses of Keytruda, in a single mission. This capability would significantly improve production efficiency and potentially bring down treatment costs. Varda aspires to be the frontrunner in demonstrating the economic viability of transporting “atoms back and forth from space,” revolutionizing the pharmaceutical industry.
This development holds immense promise for the future of medicine. By harnessing the unique environment of space, Varda paves the way for the creation of novel drugs with improved efficacy and potentially lower production costs. This space-age innovation has the potential to improve healthcare access and deliver life-saving treatments to patients worldwide. Additionally, the success of Varda’s mission opens doors for further research into the development of entirely new drugs that might only be possible under the unique microgravity conditions of space. This new frontier in pharmaceutical manufacturing holds the promise of a healthier future for all.
